We would like to share this important update from Ipsen’s leadership on the partial clinical hold for children under the age of 14 in their Phase 2 and Phase 3 clinical trials evaluating investigational palovarotene for the chronic treatment of FOP and multiple osteochondromas (MO). This action was taken following recent safety reports submitted by Ipsen to the FDA of cases of early growth plate closure in some children with FOP who received investigational drug palovarotene. The FDA is allowing the FOP clinical trials to continue in study patients ages 14 and older. Read more.